Research progress of precise targeted therapy for human epidermal growth factor receptor-2 in biliary tract cancers
10.3760/cma.j.cn113884-20230224-00048
- VernacularTitle:人表皮生长因子受体2抑制剂靶向治疗胆道恶性肿瘤的研究进展
- Author:
Haimin WENG
1
;
Jieer YING
Author Information
1. 浙江中医药大学第二临床医学院，杭州 310053
- Keywords:
Biliary tract neoplasms;
Targeted therapy;
Genes, erbB-2
- From:
Chinese Journal of Hepatobiliary Surgery
2023;29(8):636-640
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancers (BTC) are highly heterogeneous tumours. Currently, the global demand for advanced BTC treatment is far from being met, and the survival benefit from advanced chemotherapy is limited. In recent years, with the rise of precision treatment, there are more and more treatment options available for advanced BTC. Human epidermal growth factor receptor-2 (HER2) inhibitors, including monoclonal antibodies, tyrosine kinase inhibitors, antibody drug conjugates, and bispecific antibodies, have been explored in BTC. This article reviews the research progress and prospects of HER2 inhibitors in BTC in recent years, so as to provide a better clinical guidance.
